Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

Bio-Path Holdings

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2007-01-01

Employees: 10

Market Cap: -

Website: http://www.biopathholdings.com

Introduction: Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX.

Clinical Trials

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

Phase 1

Recruiting

Conditions: Acute Myeloid Leukemia, in Relapse
Acute Myeloid Leukemia Refractory

Interventions: Drug: BP1002; Liposomal Bcl-2 Antisense Oligodeoxynucleotide
Drug: Decitabine (in combination with BP1002)

First Posted Date: 2022-01-13

Last Posted Date: 2025-03-10

Lead Sponsor: Bio-Path Holdings, Inc.

Target Recruit Count: 48

Registration Number: NCT05190471

Locations: 🇺🇸
Scripps Green Hospital, La Jolla, California, United States
🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Weill Cornell Medical College - NewYork-Presbyterian Hospital, New York, New York, United States

and more 1 locations

BP1001-A in Patients With Advanced or Recurrent Solid Tumors

Phase 1

Recruiting

Conditions: Solid Tumor, Adult
Carcinoma, Ovarian Epithelial
Fallopian Tube Neoplasms
Endometrial Cancer
Peritoneal Cancer
Solid Tumor

Interventions: Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide)
Drug: BP1001-A (Liposomal Grb2 Antisense Oligonucleotide) with paclitaxel

First Posted Date: 2019-12-12

Last Posted Date: 2025-03-25

Lead Sponsor: Bio-Path Holdings, Inc.

Target Recruit Count: 50

Registration Number: NCT04196257

Locations: 🇺🇸
Holy Cross Hospital, Silver Spring, Maryland, United States
🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
Mary Crowley Cancer Research, Dallas, Texas, United States

and more 1 locations

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Phase 1

Active, not recruiting

Conditions: Waldenstrom Macroglobulinemia
Chronic Lymphocytic Leukemia (CLL)
Follicular Lymphoma
Mantle Cell Lymphoma
Cutaneous T-cell Lymphoma (CTCL)
Small Lymphocytic Lymphoma (SLL)
Marginal Zone Lymphoma
Peripheral T-cell Lymphoma (PTCL)
Hodgkin Lymphoma
DLBCL

Interventions: Drug: L-Bcl-2 antisense oligonucleotide

First Posted Date: 2019-08-28

Last Posted Date: 2025-02-24

Lead Sponsor: Bio-Path Holdings, Inc.

Target Recruit Count: 30

Registration Number: NCT04072458

Locations: 🇺🇸
Georgia Cancer Center, Augusta, Georgia, United States
🇺🇸
New York Medical College / Westchester Medical Center, Valhalla, New York, United States
🇺🇸
Sarah Cannon Research Institute/Tennesee Oncology, Nashville, Tennessee, United States

and more 2 locations

Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS

Phase 1

Withdrawn

Conditions: Acute Myeloid Leukemia
Myelodysplastic Syndrome
Chronic Myelogenous Leukemia, Ph1-Positive

Interventions: Drug: BP1001 (varying dose)
Drug: BP1001 (fixed dose)
Drug: Dasatinib

First Posted Date: 2016-10-05

Last Posted Date: 2020-05-28

Lead Sponsor: Bio-Path Holdings, Inc.

Registration Number: NCT02923986

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

Phase 2

Recruiting

Conditions: Acute Myeloid Leukemia (AML)

Interventions: Drug: BP1001 plus decitabine
Drug: BP1001 in combination with Ventoclax plus decitabine

First Posted Date: 2016-05-25

Last Posted Date: 2025-03-07

Lead Sponsor: Bio-Path Holdings, Inc.

Target Recruit Count: 108

Registration Number: NCT02781883

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
🇺🇸
University of Kansas Cancer Center, Fairway, Kansas, United States

and more 6 locations

Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS

Phase 1

Completed

Conditions: Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Ph1 Positive CML
Myelodysplastic Syndrome

Interventions: Drug: BP1001 in combination with LDAC
Drug: BP1001

First Posted Date: 2010-07-09

Last Posted Date: 2020-05-28

Lead Sponsor: Bio-Path Holdings, Inc.

Target Recruit Count: 60

Registration Number: NCT01159028

Locations: 🇺🇸
M. D. Anderson Cancer Center, Houston, Texas, United States

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy